On Monday, Esperion Therapeutics Inc (NASDAQ: ESPR) was 6.43% up from the session before settling in for the closing price of $1.4. A 52-week range for ESPR has been $0.69 – $3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 40.11% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 41.07%. With a float of $193.62 million, this company’s outstanding shares have now reached $196.66 million.
In an organization with 304 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 65.3%, operating margin of -15.4%, and the pretax margin is -59.03%.
Esperion Therapeutics Inc (ESPR) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Esperion Therapeutics Inc stocks. The insider ownership of Esperion Therapeutics Inc is 2.31%, while institutional ownership is 57.44%. The most recent insider transaction that took place on Jul 17 ’25, was worth 1,470. In this transaction General Counsel of this company sold 1,304 shares at a rate of $1.13, taking the stock ownership to the 399,937 shares. Before that another transaction happened on Jul 17 ’25, when Company’s Chief Financial Officer sold 11 for $1.11, making the entire transaction worth $12. This insider now owns 474,462 shares in total.
Esperion Therapeutics Inc (ESPR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 41.07% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
You can see what Esperion Therapeutics Inc (ESPR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Let’s dig in a bit further. During the last 5-days, its volume was 3.92 million. That was inferior than the volume of 4.73 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.38%.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 57.48%, which indicates a significant increase from 39.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1735 in the past 14 days, which was higher than the 0.0997 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1513, while its 200-day Moving Average is $1.6649.
